2-furan-3-yl-6-(4-phenyl-piperidin-1-yl)-pyrazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-furan-3-yl-6-(4-phenyl-piperidin-1-yl)-pyrazine
• 英文别名: 2-(3-Furyl)-6-(4-phenyl-1-piperidyl)pyrazine；2-(furan-3-yl)-6-(4-phenylpiperidin-1-yl)pyrazine
• 化学式: C₁₉H₁₉N₃O
• 分子量: 305.379
• InChiKey: MGIWFOLMJXLSOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES<br/>[FR] DERIVES DE LA PYRAZINE UTILISES EN TANT QUE COMPOSES EFFICACES CONTRE LES MALADIES INFECTIEUSES
  申请人：AXXIMA PHARMACEUTICALS AG

  公开号：WO2005058876A1

  公开（公告）日：2005-06-30

  The present invention relates to pyrazine derivatives according to the general formula (I) and pharmaceutically acceptable salts thereof and their use as pharmaceutical compounds as well as the use of these compounds for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases, stroke and especially for the treatment of herpesviral induced infections, including opportunistic infections as well as infections and diseases caused by human cytomegalovirus (HCMV).

  本发明涉及通式（I）所示的吡啶衍生物及其药用盐，以及它们作为药物化合物的用途，以及利用这些化合物制备用于预防和/或治疗传染病的药物组合物的用途，包括机会性疾病、朊蛋白疾病、免疫疾病、自身免疫疾病、双极和临床障碍、心血管疾病、细胞增殖性疾病、糖尿病、炎症、移植排斥反应、勃起功能障碍、神经退行性疾病、中风以及特别用于治疗由疱疹病毒引起的感染，包括机会性感染以及由人类巨细胞病毒（HCMV）引起的感染和疾病。
• PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES
  申请人：GPC Biotech AG

  公开号：EP1694670A1

  公开（公告）日：2006-08-30
• Pyrazine Derivatives As Effective Compounds Against Infectious Diseases
  申请人：Eikhoff Jan Eike

  公开号：US20080194574A1

  公开（公告）日：2008-08-14

  The present invention relates to pyrazine derivatives according to the general formula (I) and pharmaceutically acceptable salts thereof and their use as pharmaceutical compounds as well as the use of these compounds for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases, stroke and especially for the treatment of herpesviral induced infections, including opportunistic infections as well as infections and diseases caused by human cytomegalovirus (HCMV).